Pacific Biosciences (P09) Q2 2026 Earnings Report

The call presented a balanced mix of strong product and commercial momentum — notably the SPRQ-Nx launch, independent clinical validation, Revio multi-system orders, robust EMEA growth, and improving Vega ASP — alongside meaningful near-term financial and operational headwinds, including gross margin pressure from compute and manufacturing costs, lowered full-year revenue guidance, Asia Pacific revenue weakness, a decline in cash balance, and a delayed cash-flow breakeven into 2028. Management emphasized cost discipline, restructuring to reduce expenses, and confidence that SPRQ-Nx adoption will drive consumables volume and margin expansion over the back half of 2026 and into 2027.

Management lowered 2026 revenue guidance to $155–$165 million and now expects non‑GAAP gross margin of 35–37% and non‑GAAP operating expenses of $215–$220 million (down ~$5 million from the prior range); year‑end unrestricted cash is forecast at ~$175–$185 million (Q2 cash was $236.9 million), and cash‑flow breakeven is now expected in 2028 (vs. prior end‑of‑2027 target). They revised consumables pull‑through to $200,000–$225,000 per Revio system for the full year (current annualized pull‑through ~ $202,000), cited a temporary Vega manufacturing charge of ~$2.5 million, and expect the recent restructuring (≈40 roles) to cut compensation‑related expense by ~$15–$20 million in 2027 plus an additional ~$15–$20 million of annual savings as development spending winds down; SPRQ‑Nx adoption is expected to have >50% of the installed base opted in by end‑Q3 and the vast majority by year‑end, and management said cash burn should step down meaningfully in 2027.